spacer
home > ebr > spring 2002 > a new technology for biopharmaceutical analyses - microfluidic-based lab-on-a-chip
PUBLICATIONS
European Biopharmaceutical Review

A New Technology for Biopharmaceutical Analyses - Microfluidic-Based Lab-on-a-Chip

Although the term 'lab-on-a-chip' is relatively new, the concept of applying chip technology to miniaturise analytical instruments is not. Its roots can be traced back to 1975 when the first attempts were made to use chip technology to miniaturise analytical instruments such as gas chromatographs. Technical problems prevented commercial success of the initial attempts. In recent years, however, the development of the new field of microfluidics has established itself as an important research area and is starting to appear in commercial products. There is great interest within the pharmaceutical industry in lab-on-a-chip devices because they promise to speed up the discovery process by allowing researchers to perform more analyses faster, more accurately and reproducibly whilst using much smaller sample volumes than is possible with conventional technology.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tony Owen, Marketing Manager at Agilent Technologies, Germany

Dr Anthony Owen holds a degree in Chemistry and a doctorate in Physical Organic Chemistry from the University of Manchester Institute of Science and Technology. He briefly worked as a Research Chemist for Associated Octel in Ellesmere Port, UK, before joining Agilent Technologies (formerly Hewlett-Packard) in Vienna, Austria in 1979.
Since 1984 Anthony has been based in Waldbronn, Germany - firstly as Product Manager for UV-Visible spectroscopy, and since 2001 as Marketing Manager for the lab-on-a-chip products.

spacer
Dr Anthony Owen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement